Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 15 · below the Ichimoku cloud · RSI 29 (oversold) · MACD below its signal · 2% above its 52-week low
| 3.89 | 52-week high | +322.78% |
| 2.65 | Previous month high | +188.01% |
| 1.59 | Previous month low | +72.81% |
| 1.24 | Previous week high | +34.77% |
| 0.9767 | R3 (classic) | +6.15% |
| 0.9633 | R2 (classic) | +4.70% |
| 0.9500 | Previous day high | +3.25% |
| 0.9417 | R1 (classic) | +2.34% |
| 0.9283 | Pivot | +0.89% |
| 0.9201 | Price now | |
| 0.9150 | Previous day low | −0.55% |
| 0.9067 | S1 (classic) | −1.46% |
| 0.9000 | Previous week low | −2.18% |
| 0.9000 | 52-week low | −2.18% |
| 0.8933 | S2 (classic) | −2.91% |
| 0.8717 | S3 (classic) | −5.26% |
None of the 29 investors followed here reported a position in XRTX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a XRTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Dec 30, 2025 | Davies Foss (Krysta)Director of Issuer | — | 0 | — |
TimeframesDown on all 4 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -11.0 | -18.0 | -0.2 | 39.9 | -19.6 | -5.7 | -2.3 | 9.4 | -27.2 | -45.6 | −67.3% | ||
| 2025 | -15.9 | 3.2 | -2.0 | 6.2 | -7.8 | -3.7 | -20.1 | 11.2 | 0.7 | -25.6 | 7.5 | -13.3 | −50.3% |
| 2024 | 3.0 | 27.7 | 21.7 | -31.1 | 1.0 | -26.2 | -5.5 | 17.0 | -21.9 | -12.8 | -11.2 | -11.0 | −51.1% |
| 2023 | -27.0 | -0.2 | -21.1 | 37.8 | 4.2 | -2.8 | 1.7 | 1.5 | -10.4 | -49.5 | -90.1 | -5.3 | −96.5% |
| 2022 | -24.9 | -8.4 | 38.3 | -33.3 | -1.5 | 10.2 | -3.5 | -0.7 | -10.4 | -30.2 | 3.0 | -7.1 | −60.6% |
| 2021 | -41.1 | -17.4 | -12.0 | −57.2% |
No analyst coverage for this instrument.
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.